Developer docs
API playgroundTry for free, no card

Search company profiles

Sphere Bio

Full company profile

uuid0000vm3

Namestring
Sphere Bio
Legal namestring
Fluidic Sciences Ltd
Websiteurl
spherebio.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Sphere Bio, a brand of Fluidic Sciences Ltd, is a UK-based life sciences tools company specializing in picodroplet microfluidic technology for high-throughput single-cell analysis and isolation. Its core Cyto-Mine® and Cyto-Mine® Chroma platforms encapsulate individual mammalian cells in picolitre-sized aqueous droplets within a biocompatible carrier oil, where each droplet functions as an ultra-miniaturized bioreactor. This enables fluorescence-based screening of up to 40 million cells per run, FRET-based secretion assays (e.g., antibody identification), automated sorting, and documented monoclonality assurance at >99% confidence, with 21 CFR Part 11 and GLP compliance for regulated biopharmaceutical workflows. The platform is complemented by an integrated ecosystem of disposable Cyto-Cartridge® consumables, Cyto-Surf® and Pico-Surf® reagents, and Cyto-Cellect® assay kits for human/mouse IgG, Fc fusion, and viability detection.

The company sells capital equipment (Cyto-Mine instruments), recurring consumables and assay kits, and service plans to biopharma companies, CDMOs (e.g., FUJIFILM Biotechnologies, Abzena, FairJourney Biologics), large biopharma (Janssen/J&J), academic translational groups (KU Leuven's PharmAbs), and antibody discovery firms (Biointron). Distribution is direct via field sales and field application scientists, supported by content marketing (Knowledge Hub), conference presence (SLAS, PEGS, Biologics US/EU, Cell UK), and webinars. In 2025, Sphere Bio was acquired by Fluidic Sciences Ltd, integrating its single-cell screening capabilities with Fluidity One-M in-solution biophysics technology to create an end-to-end portfolio spanning multiplex single-cell screening to molecular characterization.

Funding to date totals approximately $61 million across nine rounds, with the largest being a $41.4 million round in October 2021 led by Redmile Group and Sofinnova Partners. The company holds no publicly disclosed revenue figures and is not listed on any public exchange.

Short descriptiontext

Sphere Bio (a brand of Fluidic Sciences Ltd) sells picodroplet microfluidic instruments, consumables, and assay kits for high-throughput single-cell screening and isolation, serving biopharma companies, CDMOs, and academic researchers in antibody discovery and cell line development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single cell analysis, microfluidic technology, cell line development, antibody discovery, picodroplet screening
Industry4 codes
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Surgical & Medical Instruments & Apparatus3841
Product category
Life Sciences Microfluidic Instruments
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Capital Equipment (Instrument Platforms)
TypeOne Time License
Description

Cyto-Mine® and Cyto-Mine® Chroma instruments are sold as capital equipment to biopharma companies, CDMOs, and research institutions. The platform is a benchtop system compatible with Class II biosafety cabinets.

spherebio.com
2Consumables & Reagents
TypeSubscription Recurring
Description

Recurring revenue from single-use Cyto-Cartridges®, Cyto-Surf® reagents, Pico-Surf® and Pico-Break™ droplet chemicals. These are consumed with each experimental run, creating recurring demand.

spherebio.com
3Assay Kits
TypeSubscription Recurring
Description

Specialized FRET-based assay kits (Cyto-Cellect® family) sold for use with Cyto-Mine® platforms. These include Human IgG Kappa/Viability, Plus (κ and λ), Fc Fusion, and Mouse IgG detection kits. Subject to minimum order quantities.

spherebio.com
4Service Plans & Technical Support
TypeSubscription Recurring
Description

Sphere Bio offers service plans and technical support contracts for instrument maintenance and customer success. Remote diagnostics and field service labour are included under warranty.

spherebio.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details4 tiers
1Capital instruments - Cyto-Mine® and Cyto-Mine® Chroma platforms
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Not publicly disclosed. Quote-based sales through sales team.

spherebio.com
2Assay Kits - Cyto-Cellect® product family
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Not publicly disclosed. Subject to minimum order quantity for some products (e.g., Cyto-Cellect® Fc Fusion Assay Kit).

spherebio.com
3Consumables - Cyto-Cartridges®, Cyto-Surf®, Pico-Surf®, Pico-Break™
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Not publicly disclosed. Recurring purchase based on experimental run frequency.

spherebio.com
4Service Plans - maintenance and technical support
ModelSubscriptionBilling cadenceAnnual
Notes

Not publicly disclosed. Includes remote diagnostics and field service during warranty period. Annual maintenance recommended post-warranty.

spherebio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Cyto-Mine®
Description

Automated single-cell analysis and isolation platform using picodroplet microfluidic technology for antibody discovery and cell line development.

spherebio.com
+3 more records
Core offering1 text field

Sphere Bio develops picodroplet microfluidic instruments (Cyto-Mine® and Cyto-Mine® Chroma) for high-throughput single-cell analysis and isolation, enabling screening of up to 40 million cells per day. The offering is supported by a proprietary ecosystem of single-use Cyto-Cartridge® consumables, Cyto-Surf® and Pico-Surf® reagents, Pico-Break™ emulsion-breaking solutions, and the Cyto-Cellect® family of FRET-based assay kits for antibody discovery and cell line development applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 40 million cells screened per day
+6 more records
Product overview1 text field

Sphere Bio offers a unified platform-plus-consumables architecture centered on picodroplet microfluidic technology. The core Cyto-Mine® and Cyto-Mine® Chroma platforms automate single-cell analysis and isolation, while a suite of Cyto-Cellect® assay kits (for Human IgGκ, Human IgG κ/λ, Fc Fusion, Mouse IgG, and combined viability detection) provide application-specific fluorescence detection capabilities. The ecosystem is supported by Cyto-Cartridge® consumables, Cyto-Surf® reagents, and Pico-Surf®/Pico-Break™ droplet microfluidics chemicals. All products are designed for antibody discovery, cell line development, cell therapy, cell engineering, and synthetic biology applications.

Product and service16 records
1Cyto-Mine®
CategoryPlatform Instrument
Description

Automated high-throughput single-cell analysis and isolation platform using picodroplet microfluidic technology that processes up to 40 million heterogeneous mammalian cells per run and screens individual cells within a single day for antibody discovery and cell line development applications. Designed for biopharma companies, CDMOs, and research institutions.

2Cyto-Mine® Chroma
CategoryPlatform Instrument
Description

Next-generation automated single-cell analysis and isolation platform featuring four lasers across independent colour channels for enhanced fluorescence detection and multiplexed assays, enabling co-encapsulation of antibody-secreting cells and target cells for functional assays and serial gating during sorting. Designed for biopharma antibody discovery and cell line development workflows.

3Cyto-Cellect® (Human IgGκ) Assay Kit
CategoryAssay Kit
Description

Sensitive, easy-to-use, animal-origin-free FRET-based assay kit to detect cell clone productivity by identifying human IgG kappa secretion in picodroplets, used with Cyto-Mine® platforms for cell line development and antibody discovery workflows.

4Cyto-Cellect® Plus (Human IgG κ and λ) Assay Kit
CategoryAssay Kit
Description

Dual light chain detection assay kit enabling quantification of secreted IgG with either kappa or lambda light chains in a single assay for use with Cyto-Mine® platforms. Screens up to 40 million cells per day; animal-origin-free and suitable for therapeutic workflows.

5Cyto-Cellect® Fc Fusion Assay Kit
CategoryAssay Kit
Description

FRET-based competition assay kit for detection of human Fc fusion proteins containing human IgG Fc region in picodroplets, enabling high-efficiency cell line development for Fc fusion protein manufacturing. Detects all four human IgG subclasses and Fc-silent mutated Fc domains; animal-origin-free certified.

6Cyto-Cellect® Mouse (Mouse IgG Detection Kit)
CategoryAssay Kit
Description

Sensitive and robust assay kit to detect mouse IgG antibodies in picodroplets, designed for use with Cyto-Mine® platforms to support antibody discovery workflows using murine systems.

7Cyto-Cellect® Human IgG Kappa and Viability Assay Kit
CategoryAssay Kit
Description

Multiplexed assay kit for Cyto-Mine® Chroma enabling simultaneous real-time detection of human IgG-secreting cells and identification of apoptotic/necrotic cells, using Cyto-Cellect® human IgGk FRET probes and a customized viability dye targeting apoptotic/necrotic cell membranes.

8Cyto-Cartridge®
CategoryConsumable
Description

Disposable microfluidic cartridge providing all necessary microfluidics for implementing picodroplet workflows on Cyto-Mine® platforms. Designed for ease of use, zero cross-contamination between runs, and maintenance of cell integrity.

9Cyto-Surf® A
CategoryReagent
Description

Specialist chemical and bioreagent optimized for use with Cyto-Mine® platforms to maintain cell viability in picodroplets, part of the consumables ecosystem for picodroplet workflows.

10Cyto-Surf® B
CategoryReagent
Description

Specialist chemical and bioreagent optimized for use with Cyto-Mine® platforms to maintain cell viability in picodroplets, part of the consumables ecosystem for picodroplet workflows.

11Pico-Surf® (2% w/w in fluorinated oil)
CategoryReagent
Description

Fluorinated surfactant (2% w/w) in fluorinated oil available as a Novec 7500 alternative, used for generating stable picodroplets in droplet microfluidics workflows.

12Pico-Surf® (5% w/w in fluorinated oil)
CategoryReagent
Description

Fluorinated surfactant (5% w/w) in fluorinated oil for generating stable picodroplets in droplet microfluidics workflows.

13Pico-Surf® (2% w/w in Novec™ 7500)
CategoryReagent
Description

Fluorinated surfactant (2% w/w) in Novec 7500 carrier fluid for generating biocompatible picodroplets in droplet microfluidics workflows.

14Pico-Surf® (5% w/w in Novec™ 7500)
CategoryReagent
Description

High-concentration fluorinated surfactant (5% w/w) in Novec 7500 carrier fluid for picodroplet generation in droplet microfluidics workflows.

15Pico-Break™
CategoryReagent
Description

Emulsion breaking solution for recovering cells or materials from picodroplet emulsions after analysis, part of the consumables ecosystem for picodroplet workflows.

16Service Plans & Technical Support
CategoryService
Description

Service plans and technical support contracts for instrument maintenance and customer success, including remote diagnostics and field service labour during the warranty period, with annual maintenance recommended post-warranty.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fluidic Sciences Ltd acquired the business and assets of Sphere Bio, integrating Sphere Bio's single-cell analysis platforms (Cyto-Mine®) with Fluidic Sciences' protein interaction analysis technologies (Fluidity One-M, Fluidity Insight). The acquisition expands applications across antibody discovery, cell line development, cell therapy, and complex protein interaction analysis, creating an end-to-end portfolio from single-cell screening to in-solution biophysics.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Diversified life sciences tools giant offering flow cytometry (Attune, Bigfoot), cell line development services, and bioproduction reagents that overlap with Sphere Bio's customer workflows.

TypeBroad incumbent
Description

Major flow cytometry and laboratory automation player (CytoFLEX, MoFlo Astrios). Broad incumbent with overlapping capabilities in cell sorting and biopharma workflow integration.

TypeBroad incumbent
Description

Major flow cytometry (ZE5, S3e) and life science research tools provider; broad incumbent with overlapping capabilities in cell sorting, antibody discovery reagents, and biopharma QC.

TypeEmerging player
Description

Single-cell genomics and multi-omics platform (Tapestri) used in cell therapy QC and clonality analysis; intersects with Sphere Bio's monoclonality assurance and cell therapy positioning.

TypeBroad incumbent
Description

Global leader in flow cytometry instruments, cell sorters (FACSDiscover, FACSAria), and reagents. Competes in the same end applications (antibody discovery, cell line development) via a much broader installed base.

TypeDirect peer
Description

Direct competitor in automated single-cell analysis and isolation platforms (Beacon/OptoSelect lightning technology) for antibody discovery and cell line development. Both target biopharma and CDMO customers with high-throughput single-cell screening and monoclonality assurance.

TypeEmerging player
Description

Chromium single-cell platform for genomics and immune profiling; overlaps with Sphere Bio in antibody discovery and B-cell receptor workflows, but with a sequencing-based rather than picodroplet-screening approach.

TypeDirect peer
Description

Droplet-based miniaturized immunoassay platform (Curiox Laminar Wash, DropArray) for single-cell and multiplexed bioassays; serves similar biopharma and CDMO use cases in cell-based screening.

9Sony Biotechnology
TypeBroad incumbent
Description

Provides high-speed cell sorters (SH800, MA900) and microfluidic cell sorters (Cell Sorter SH800S) used in antibody discovery and cell line development workflows.

TypeDirect peer
Description

Single-cell printing and cloning platform using droplet microfluidics (cy-Clone, C.BIRD) for cell line development and antibody discovery. Directly comparable picodroplet-based approach and customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sphere Bio

Life Sciences Microfluidic Instrumentsspherebio.com

Sphere Bio (a brand of Fluidic Sciences Ltd) sells picodroplet microfluidic instruments, consumables, and assay kits for high-throughput single-cell screening and isolation, serving biopharma companies, CDMOs, and academic researchers in antibody discovery and cell line development.

What Sphere Bio does

Sphere Bio, a brand of Fluidic Sciences Ltd, is a UK-based life sciences tools company specializing in picodroplet microfluidic technology for high-throughput single-cell analysis and isolation. Its core Cyto-Mine® and Cyto-Mine® Chroma platforms encapsulate individual mammalian cells in picolitre-sized aqueous droplets within a biocompatible carrier oil, where each droplet functions as an ultra-miniaturized bioreactor. This enables fluorescence-based screening of up to 40 million cells per run, FRET-based secretion assays (e.g., antibody identification), automated sorting, and documented monoclonality assurance at >99% confidence, with 21 CFR Part 11 and GLP compliance for regulated biopharmaceutical workflows. The platform is complemented by an integrated ecosystem of disposable Cyto-Cartridge® consumables, Cyto-Surf® and Pico-Surf® reagents, and Cyto-Cellect® assay kits for human/mouse IgG, Fc fusion, and viability detection.

The company sells capital equipment (Cyto-Mine instruments), recurring consumables and assay kits, and service plans to biopharma companies, CDMOs (e.g., FUJIFILM Biotechnologies, Abzena, FairJourney Biologics), large biopharma (Janssen/J&J), academic translational groups (KU Leuven's PharmAbs), and antibody discovery firms (Biointron). Distribution is direct via field sales and field application scientists, supported by content marketing (Knowledge Hub), conference presence (SLAS, PEGS, Biologics US/EU, Cell UK), and webinars. In 2025, Sphere Bio was acquired by Fluidic Sciences Ltd, integrating its single-cell screening capabilities with Fluidity One-M in-solution biophysics technology to create an end-to-end portfolio spanning multiplex single-cell screening to molecular characterization.

Funding to date totals approximately $61 million across nine rounds, with the largest being a $41.4 million round in October 2021 led by Redmile Group and Sofinnova Partners. The company holds no publicly disclosed revenue figures and is not listed on any public exchange.

Sphere Bio firmographics

Firmographics
Name
Sphere Bio
Legal name
Fluidic Sciences Ltd
Website
https://spherebio.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
Sphere Bio (a brand of Fluidic Sciences Ltd) sells picodroplet microfluidic instruments, consumables, and assay kits for high-throughput single-cell screening and isolation, serving biopharma companies, CDMOs, and academic researchers in antibody discovery and cell line development.
Ownership category
akta.pro rank

Sphere Bio industry classification

Industry
Product category
Life Sciences Microfluidic Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)

Keywords

  • Single cell analysis
  • Microfluidic technology
  • Cell line development
  • Antibody discovery
  • Picodroplet screening

Where Sphere Bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Sphere Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Capital Equipment (Instrument Platforms): Cyto-Mine® and Cyto-Mine® Chroma instruments are sold as capital equipment to biopharma companies, CDMOs, and research institutions. The platform is a benchtop system compatible with Class II biosafety cabinets.
  2. Consumables & Reagents: Recurring revenue from single-use Cyto-Cartridges®, Cyto-Surf® reagents, Pico-Surf® and Pico-Break™ droplet chemicals. These are consumed with each experimental run, creating recurring demand.
  3. Assay Kits: Specialized FRET-based assay kits (Cyto-Cellect® family) sold for use with Cyto-Mine® platforms. These include Human IgG Kappa/Viability, Plus (κ and λ), Fc Fusion, and Mouse IgG detection kits. Subject to minimum order quantities.
  4. Service Plans & Technical Support: Sphere Bio offers service plans and technical support contracts for instrument maintenance and customer success. Remote diagnostics and field service labour are included under warranty.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractCapital instruments - Cyto-Mine® and Cyto-Mine® Chroma platforms
Unit PricingPay-as-you-goAssay Kits - Cyto-Cellect® product family
Unit PricingPay-as-you-goConsumables - Cyto-Cartridges®, Cyto-Surf®, Pico-Surf®, Pico-Break™
SubscriptionAnnualService Plans - maintenance and technical support

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Sphere Bio product offering

Product offering

Core offering

Sphere Bio develops picodroplet microfluidic instruments (Cyto-Mine® and Cyto-Mine® Chroma) for high-throughput single-cell analysis and isolation, enabling screening of up to 40 million cells per day. The offering is supported by a proprietary ecosystem of single-use Cyto-Cartridge® consumables, Cyto-Surf® and Pico-Surf® reagents, Pico-Break™ emulsion-breaking solutions, and the Cyto-Cellect® family of FRET-based assay kits for antibody discovery and cell line development applications.

Product overview

Sphere Bio offers a unified platform-plus-consumables architecture centered on picodroplet microfluidic technology. The core Cyto-Mine® and Cyto-Mine® Chroma platforms automate single-cell analysis and isolation, while a suite of Cyto-Cellect® assay kits (for Human IgGκ, Human IgG κ/λ, Fc Fusion, Mouse IgG, and combined viability detection) provide application-specific fluorescence detection capabilities. The ecosystem is supported by Cyto-Cartridge® consumables, Cyto-Surf® reagents, and Pico-Surf®/Pico-Break™ droplet microfluidics chemicals. All products are designed for antibody discovery, cell line development, cell therapy, cell engineering, and synthetic biology applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Cyto-Mine®: Automated single-cell analysis and isolation platform using picodroplet microfluidic technology for antibody discovery and cell line development.
  • Cyto-Mine® Chroma
  • Cyto-Cellect®
  • Cyto-Cartridge®

Products and services

  • Cyto-Mine® Automated high-throughput single-cell analysis and isolation platform using picodroplet microfluidic technology that processes up to 40 million heterogeneous mammalian cells per run and screens individual cells within a single day for antibody discovery and cell line development applications. Designed for biopharma companies, CDMOs, and research institutions.
  • Cyto-Mine® Chroma Next-generation automated single-cell analysis and isolation platform featuring four lasers across independent colour channels for enhanced fluorescence detection and multiplexed assays, enabling co-encapsulation of antibody-secreting cells and target cells for functional assays and serial gating during sorting. Designed for biopharma antibody discovery and cell line development workflows.
  • Cyto-Cellect® (Human IgGκ) Assay Kit Sensitive, easy-to-use, animal-origin-free FRET-based assay kit to detect cell clone productivity by identifying human IgG kappa secretion in picodroplets, used with Cyto-Mine® platforms for cell line development and antibody discovery workflows.
  • Cyto-Cellect® Plus (Human IgG κ and λ) Assay Kit Dual light chain detection assay kit enabling quantification of secreted IgG with either kappa or lambda light chains in a single assay for use with Cyto-Mine® platforms. Screens up to 40 million cells per day; animal-origin-free and suitable for therapeutic workflows.
  • Cyto-Cellect® Fc Fusion Assay Kit FRET-based competition assay kit for detection of human Fc fusion proteins containing human IgG Fc region in picodroplets, enabling high-efficiency cell line development for Fc fusion protein manufacturing. Detects all four human IgG subclasses and Fc-silent mutated Fc domains; animal-origin-free certified.
  • Cyto-Cellect® Mouse (Mouse IgG Detection Kit) Sensitive and robust assay kit to detect mouse IgG antibodies in picodroplets, designed for use with Cyto-Mine® platforms to support antibody discovery workflows using murine systems.
  • Cyto-Cellect® Human IgG Kappa and Viability Assay Kit Multiplexed assay kit for Cyto-Mine® Chroma enabling simultaneous real-time detection of human IgG-secreting cells and identification of apoptotic/necrotic cells, using Cyto-Cellect® human IgGk FRET probes and a customized viability dye targeting apoptotic/necrotic cell membranes.
  • Cyto-Cartridge® Disposable microfluidic cartridge providing all necessary microfluidics for implementing picodroplet workflows on Cyto-Mine® platforms. Designed for ease of use, zero cross-contamination between runs, and maintenance of cell integrity.
  • Cyto-Surf® A Specialist chemical and bioreagent optimized for use with Cyto-Mine® platforms to maintain cell viability in picodroplets, part of the consumables ecosystem for picodroplet workflows.
  • Cyto-Surf® B Specialist chemical and bioreagent optimized for use with Cyto-Mine® platforms to maintain cell viability in picodroplets, part of the consumables ecosystem for picodroplet workflows.
  • Pico-Surf® (2% w/w in fluorinated oil) Fluorinated surfactant (2% w/w) in fluorinated oil available as a Novec 7500 alternative, used for generating stable picodroplets in droplet microfluidics workflows.
  • Pico-Surf® (5% w/w in fluorinated oil) Fluorinated surfactant (5% w/w) in fluorinated oil for generating stable picodroplets in droplet microfluidics workflows.
  • Pico-Surf® (2% w/w in Novec™ 7500) Fluorinated surfactant (2% w/w) in Novec 7500 carrier fluid for generating biocompatible picodroplets in droplet microfluidics workflows.
  • Pico-Surf® (5% w/w in Novec™ 7500) High-concentration fluorinated surfactant (5% w/w) in Novec 7500 carrier fluid for picodroplet generation in droplet microfluidics workflows.
  • Pico-Break™ Emulsion breaking solution for recovering cells or materials from picodroplet emulsions after analysis, part of the consumables ecosystem for picodroplet workflows.
  • Service Plans & Technical Support Service plans and technical support contracts for instrument maintenance and customer success, including remote diagnostics and field service labour during the warranty period, with annual maintenance recommended post-warranty.

Quantifiable outcome

  • 40 million cells screened per day
  • +6 more outcomes

Companies that use Sphere Bio

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Sphere Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

Sphere Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Fluidic Sciences LtdcoreStrategic or Co-development PartnerFluidic Sciences Ltd acquired the business and assets of Sphere Bio, integrating Sphere Bio's single-cell analysis platforms (Cyto-Mine®) with Fluidic Sciences' protein interaction analysis technologies (Fluidity One-M, Fluidity Insight). The acquisition expands applications across antibody discovery, cell line development, cell therapy, and complex protein interaction analysis, creating an end-to-end portfolio from single-cell screening to in-solution biophysics.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Sphere Bio competitors and assessment

Company assessment

Broad incumbents

  • Thermo Fisher Scientific: Diversified life sciences tools giant offering flow cytometry (Attune, Bigfoot), cell line development services, and bioproduction reagents that overlap with Sphere Bio's customer workflows.
  • Beckman Coulter Life Sciences (Danaher): Major flow cytometry and laboratory automation player (CytoFLEX, MoFlo Astrios). Broad incumbent with overlapping capabilities in cell sorting and biopharma workflow integration.
  • Bio-Rad Laboratories: Major flow cytometry (ZE5, S3e) and life science research tools provider; broad incumbent with overlapping capabilities in cell sorting, antibody discovery reagents, and biopharma QC.
  • BD Biosciences (Becton Dickinson): Global leader in flow cytometry instruments, cell sorters (FACSDiscover, FACSAria), and reagents. Competes in the same end applications (antibody discovery, cell line development) via a much broader installed base.
  • Sony Biotechnology: Provides high-speed cell sorters (SH800, MA900) and microfluidic cell sorters (Cell Sorter SH800S) used in antibody discovery and cell line development workflows.

Emerging players

  • Mission Bio: Single-cell genomics and multi-omics platform (Tapestri) used in cell therapy QC and clonality analysis; intersects with Sphere Bio's monoclonality assurance and cell therapy positioning.
  • 10x Genomics: Chromium single-cell platform for genomics and immune profiling; overlaps with Sphere Bio in antibody discovery and B-cell receptor workflows, but with a sequencing-based rather than picodroplet-screening approach.

Direct peers

  • Berkeley Lights (now PhenomeX): Direct competitor in automated single-cell analysis and isolation platforms (Beacon/OptoSelect lightning technology) for antibody discovery and cell line development. Both target biopharma and CDMO customers with high-throughput single-cell screening and monoclonality assurance.
  • Curiox Biosystems: Droplet-based miniaturized immunoassay platform (Curiox Laminar Wash, DropArray) for single-cell and multiplexed bioassays; serves similar biopharma and CDMO use cases in cell-based screening.
  • Cytena (part of BICO/CELLINK): Single-cell printing and cloning platform using droplet microfluidics (cy-Clone, C.BIRD) for cell line development and antibody discovery. Directly comparable picodroplet-based approach and customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Sphere Bio social profiles

Digital presence

Sphere Bio compliance and trust

Trust signal

Compliance2 records

Sphere Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sphere Bio leadership team

Management profile

Number of profiles

Profiles12 records

Sphere Bio funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sphere Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sphere Bio

What does Sphere Bio do?

Sphere Bio develops picodroplet microfluidic instruments (Cyto-Mine® and Cyto-Mine® Chroma) for high-throughput single-cell analysis and isolation, enabling screening of up to 40 million cells per day. The offering is supported by a proprietary ecosystem of single-use Cyto-Cartridge® consumables, Cyto-Surf® and Pico-Surf® reagents, Pico-Break™ emulsion-breaking solutions, and the Cyto-Cellect® family of FRET-based assay kits for antibody discovery and cell line development applications.

Is Sphere Bio a public or private company?

Sphere Bio is a private company. It is classified as corporate owned and is currently operating.

When was Sphere Bio founded?

Sphere Bio was founded in 2010. It employs 51 to 100 people.

Where is Sphere Bio based?

Sphere Bio is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Sphere Bio make money?

Four revenue lines are on record. Capital Equipment (Instrument Platforms) is the primary driver. The others are consumables & Reagents, assay Kits and service Plans & Technical Support.

Who are Sphere Bio's main competitors?

Broad incumbents on record are Thermo Fisher Scientific, Beckman Coulter Life Sciences (Danaher), Bio-Rad Laboratories, BD Biosciences (Becton Dickinson) and Sony Biotechnology. Emerging players are Mission Bio and 10x Genomics. Direct peers are Berkeley Lights (now PhenomeX), Curiox Biosystems and Cytena (part of BICO/CELLINK).

Does Sphere Bio have an API?

No public API is recorded for Sphere Bio.

What industry is Sphere Bio in?

Sphere Bio's product category is Life Sciences Microfluidic Instruments. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSphere Fluidics Appoints Richard Hammond as Chief Technical OfficerSphere Fluidics appointed Richard Hammond as Chief Technical Officer. He will drive innovation and productize patented prototypes for single cell analysis. The appointment supports expansion of its microfluidic product range and international growth.BioSpaceBioSpace Movers & Shakers: Singular Genomics, Marengo, Ventyx, Caribou and MoreLife sciences companies announced new leadership appointments, including Singular Genomics forming a scientific advisory board, Marengo Therapeutics naming Ke Liu as chief development officer, and Oncurus appointing Richard Wanstall as CFO. Other companies such as DNA Script, Sphere Fluidics, and Evolve also named new executives.GlobeNewswireGlobal Single-Cell Analysis Market estimated at $2.1 Billion (2020), is growing at a CAGR of 17.8% through 2020-2025The global single-cell analysis market is estimated at $2.1 billion in 2020, growing at a 17.8% CAGR through 2025. The market is driven by life science and oncology research, with investor funding such as $100 million for Singleron Biotechnologies and $40 million for Sphere Fluidics. The U.S. is the largest regional market, with Asia-Pacific growing fastest.UKTNCambridge-based Sphere Fluidics ramps up $40M for single cell analysis technology - UKTNSphere Fluidics closed a $40 million investment round led by Sofinnova Partners and Redmile Group. The funds will expand international sales, customer support, and R&D for its Cyto-Mine single cell analysis system. The company plans to broaden adoption into cell therapy, synthetic biology, and genome editing.Business Wire BlogSphere Fluidics Closes a $40 Million Funding Round Led by Sofinnova Partners and Redmile GroupSphere Fluidics closed a $40 million funding round led by Sofinnova Partners and Redmile Group. The company will use the funds to expand international sales, support, and R&D for its Cyto-Mine single cell analysis system. The investment will also broaden adoption into cell therapy, synthetic biology, and genome editing.BioSpaceSphere Fluidics Closes a $40 Million Funding Round Led by Sofinnova Partners and Redmile GroupSphere Fluidics, a Cambridge, England company developing single cell analysis systems using proprietary picodroplet technology, announced on Oct. 28, 2021 that it closed a $40 million (about £30 million) round led by Sofinnova Partners and Redmile Group on equal terms. The company said the funds will expand international sales, customer support and R&D, including the Cyto-Mine platform. Tom Burt and Rob Faulkner will join the board.Cambridge IndependentSphere Fluidics teams up with ClexBio for hydrogel kit that enables researchers to study cells for longerSphere Fluidics and ClexBio have launched the CYTRIX Microfluidic Hydrogel Kit, a biocompatible solution combining ClexBio's hydrogel with Sphere Fluidics' biochip to enable longer-term 3D cell culture studies. The kit allows researchers to maintain cell viability for weeks by overcoming common technical issues like clogging and temperature sensitivity associated with existing methods. This collaboration provides a commercial tool for tissue engineering and drug discovery applications.Cambridge NetworkSphere Fluidics announces enhanced Cyto-Mine capability and performanceSphere Fluidics announced an enhanced Cyto-Mine system with a simplified design that reduces manufacturing time and improves functionality. The update includes new electronics and software to boost performance, reliability, and user experience, aiming to streamline antibody discovery and cell therapy workflows.News-MedicalIntegrated micro-plate handling and single cell analysisSphere Fluidics and Peak Analysis and Automation integrated the Cyto-Mine single cell analysis system with PAA's S-LAB automated plate handler. The combined system processes up to 40 million mammalian cells in a few hours, reducing hands-on work and timelines in antibody discovery and cell line development.News-MedicalCyto-Cellect Human IgGK Detection KitSphere Fluidics introduced the Cyto-Cellect Human IgGK Detection Kit for its Cyto-Mine single-cell analysis system, enabling rapid detection of secreted human IgG with kappa light chain. The FRET-based assay is animal-origin-free and designed to streamline cell line development by identifying high-productivity cells.